Medication Management
Expert articles and analysis related to medication management.
AI Summary — Last 7 Days
Medication management is becoming a sharper VBC cost-control battleground as CMS’s GLP-1 Bridge pilot moves from launch to operational oversight, with Medicare obesity coverage beginning July 1 and CMS preparing to share utilization data with payers—raising immediate questions about benefit design, adherence management, risk adjustment, and whether ACOs/MA plans can translate high-cost GLP-1 use into measurable cardiometabolic outcomes. At the same time, drug-spend pressure is broadening beyond GLP-1s: Medicare Part B drug spending continues to rise while service-based utilization remains flat, and scrutiny of Medicare drug-price negotiation timing—such as the asserted delay for an AbbVie blockbuster—signals growing tension between pharmaceutical access, federal savings, and accountability for total cost of care (GLP-1 pilot rollout; [Medicare drug spending trend](https://www.trillianthealth.com/e3t/Ctc/T7+113/cslQM04/MWClZcvsTM7W1bkyL-8x-QM-W56dvtZ5SnygtN5j5FPl5kvg8W50kH_H6lZ3lyW7d3JD827ZbQpW79R
Related Articles
STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts
A little-noticed government policy shift caused a seven-year delay in choosing a costly medicine for Medicare price negotiations, an advocacy group says.
Myths Of Mandatory International Reference Pricing For Prescription Drugs
Myths Of Mandatory International Reference Pricing For Prescription Drugs Health Affairs
Q&A: FTC Settlements, PBM Reform Are Reshaping Transparency Standards
Medicaid Subscription-Based Payment Models For Hep C Drugs In Louisiana & Washington State Had A Larger Impact In Louisiana Due To Policy Factors - open minds
Medicaid Subscription-Based Payment Models For Hep C Drugs In Louisiana & Washington State Had A Larger Impact In Louisiana Due To Policy Factors open minds
Senate Unveils Sweeping Bill to Reform 340B Drug Program
Congress advances new wave of 340B legislation: What to know
Congress advances new wave of 340B legislation: What to know Becker's Hospital Review
The FTC’s Targeting of Drug-Inflating PBM Practices
Health Plans, PBMs Wary of TrumpRx Impact on Patients
CMS’s proposed SDRA methodologies for IPAY 2018 of the MDPNP could result in materially different refund obligations across products based on their competitive and discount profiles.Mitchell FinkelMar...
Effectuation and SDRA: The Dilemma of Competitive Drug Classes
Effectuation and SDRA: The Dilemma of Competitive Drug Classes Avalere Health Advisory